Order Sucraid®
Important Safety Information
Prescribing Information
Patient Site

Could it
be CSID?

For patients with unresolved gas,
bloating, abdominal pain, diarrhea,
or nausea, consider Congenital
Sucrase-Isomaltase Deficiency (CSID).

Sucraid® Treats Sucrase Deficiency
Caused by CSID

Learn how to order Sucraid® from the specialty pharmacy.

What is Sucraid®?

Sucraid® is an enzyme replacement therapy that contains sacrosidase as a substitute for sucrase, which is one of the enzymes that is defective in individuals who have sucrase deficiency caused by Congenital Sucrase-Isomaltase Deficiency (CSID). Sacrosidase facilitates the breakdown of sucrose (sugar) into its constituent monosaccharide units, glucose and fructose, for absorption from the small intestine. Sucraid® has been documented to help relieve the gastrointestinal symptoms associated with sucrase deficiency caused by CSID, and as a result, help affected individuals consume a more normal diet that includes sucrose-containing foods.

Read More

What are you 
missing? Could it be CSID?

Sucrase deficiency caused by Congenital Sucrase-Isomaltase Deficiency (CSID) is an autosomal recessive disorder that causes a deficiency in sucrase-isomaltase (SI), the enzyme responsible for the metabolism of sucrose and other sugars found in starch, and the subsequent absorption of their metabolites, glucose and fructose.

Read More

How to
diagnose CSID

CSID is largely a clinical diagnosis, but there are diagnostic tools to assess sucrase enzyme activity.

Diagnosing CSID

How to order
Sucraid®

Sucraid® is only available through an exclusive specialty pharmacy provider that ships the therapy directly to the patient’s home or physician’s office.

How to Order

Sucraid® treats sucrase deficiency caused by CSID.
The only FDA-approved enzyme replacement therapy.

Sucraid®
 4-Day Trial

Download the Sucraid® 4-Day Trial Rx form
and see if Sucraid® is right for your patients.

Sucraid® 
mechanism of action

About Sucraid®

Effective

Patients who became asymptomatic* with Sucraid® in a clinical trial.1

*Patients who took Sucraid® with each meal were considered asymptomatic if they reported no watery stools and no or mild GI symptoms for at least 7 of the 10 study days.

Proper dosing 
is essential!

The proper Sucraid® dose depends on the patient’s body weight.

Learn more about 
Sucraid®

Learn more about
CSID in children

Explore

Important information
for healthcare
professionals

Explore

Learn more about
CSID in adults

Explore

Dr. William Chey

Watch Now

Download templates 
for Letters of Medical Necessity

Biopsy

Genetic Test

History

Activity

RX Trial

Sucrose Challenge

Specialty
pharmacy

Learn how to order Sucraid®
from the specialty pharmacy.

How to Order
References
  1. Treem WR, McAdams L, Stanford L, Kastoff G, Justinich C, Hyams J. Sacrosidase therapy for congenital sucrase-isomaltase deficiency. J Pediatr Gastroenterol Nutr. 1999;28(2):137-142. doi:10.1097/00005176-199902000-00008
Important Safety Information for Sucraid® (sacrosidase) Oral Solution
Indication

Sucraid® (sacrosidase) Oral Solution is indicated for the treatment of sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID), in adult and pediatric patients 5 months of age and older.

Contraindication

Sucraid® is contraindicated in patients known to be hypersensitive to yeast, yeast products, glycerin (glycerol), or papain.

Warnings, Precautions, and Additional Important Safety Information
  • Severe Hypersensitivity Reactions
    Severe hypersensitivity reactions, including wheezing, difficulty breathing, rash, pruritis, and swelling of the face, lips, mouth, or tongue have been reported with administration of Sucraid®. Sucraid® contains papain, which is associated with hypersensitivity reactions.
  • Increased Blood Glucose Concentration in Patients With Diabetes Mellitus
    Sucraid® enables the products of sucrose hydrolysis, glucose and fructose, to be absorbed and may increase blood glucose concentrations. Monitor blood glucose concentrations and adjust the diet accordingly for patients with diabetes mellitus.
  • Dietary Starch Restriction
    Sucraid® does not replace isomaltase. Therefore, patients may still experience symptoms of CSID while taking Sucraid®. Consider dietary starch restriction in addition to Sucraid®, especially in patients in whom symptoms are not adequately controlled by Sucraid®.
  • Adverse reactions as a result of taking Sucraid® may include worse abdominal pain, vomiting, nausea, diarrhea, constipation, difficulty sleeping, headache, nervousness, and dehydration.
  • The effects of Sucraid® have not been evaluated in patients with secondary (acquired) disaccharidase deficiency.
  • DO NOT HEAT SOLUTIONS CONTAINING SUCRAID®. Do not put Sucraid® in warm or hot fluids. Do not reconstitute or consume Sucraid® with fruit juice since the acidity of the juice may reduce the enzyme activity of Sucraid®. Half of the reconstituted Sucraid® should be taken at the beginning of the meal or snack and the other half during the meal or snack.
  • Sucraid® should be refrigerated at 36°F-46°F (2°C-8°C) and should be protected from heat and light; single-use containers can be removed from refrigeration and stored at 59°F-77°F (15°C-25°C) for up to 3 days (72 hours). Refer to Instructions for Use for full information on how to take Sucraid®.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

IMPORTANT SAFETY INFORMATION:

Important Safety Information for Sucraid® (sacrosidase) Oral Solution

Indication

Sucraid® (sacrosidase) Oral Solution is indicated for the treatment of sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID), in adult and pediatric patients 5 months of age and older.

Contraindication

Sucraid® is contraindicated in patients known to be hypersensitive to yeast, yeast products, glycerin (glycerol), or papain.

Warnings, Precautions, and Additional Important Safety Information

  • Severe Hypersensitivity Reactions
    Severe hypersensitivity reactions, including wheezing, difficulty breathing, rash, pruritis, and swelling of the face, lips, mouth, or tongue have been reported with administration of Sucraid®. Sucraid® contains papain, which is associated with hypersensitivity reactions.
  • Increased Blood Glucose Concentration in Patients With Diabetes Mellitus
    Sucraid® enables the products of sucrose hydrolysis, glucose and fructose, to be absorbed and may increase blood glucose concentrations. Monitor blood glucose concentrations and adjust the diet accordingly for patients with diabetes mellitus.
  • Dietary Starch Restriction
    Sucraid® does not replace isomaltase. Therefore, patients may still experience symptoms of CSID while taking Sucraid®. Consider dietary starch restriction in addition to Sucraid®, especially in patients in whom symptoms are not adequately controlled by Sucraid®.
  • Adverse reactions as a result of taking Sucraid® may include worse abdominal pain, vomiting, nausea, diarrhea, constipation, difficulty sleeping, headache, nervousness, and dehydration.
  • The effects of Sucraid® have not been evaluated in patients with secondary (acquired) disaccharidase deficiency.
  • DO NOT HEAT SOLUTIONS CONTAINING SUCRAID®. Do not put Sucraid® in warm or hot fluids. Do not reconstitute or consume Sucraid® with fruit juice since the acidity of the juice may reduce the enzyme activity of Sucraid®. Half of the reconstituted Sucraid® should be taken at the beginning of the meal or snack and the other half during the meal or snack.
  • Sucraid® should be refrigerated at 36°F-46°F (2°C-8°C) and should be protected from heat and light; single-use containers can be removed from refrigeration and stored at 59°F-77°F (15°C-25°C) for up to 3 days (72 hours). Refer to Instructions for Use for full information on how to take Sucraid®.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

Coming soon.